England and Wales open for potential Leo Pharma recommendation
The National Institute for Health and Care Excellence (NICE) says it’s still possible for Leo Pharma to receive a recommendation for atopic eczema treatment Adtralza, and is currently reviewing comments from the firm.
by ulrich quistgaard, translated by daniel pedersen
The public body responsible for providing guidance and advice for England and Wales, the National Institute for Health and Care Excellence (NICE), is now clarifying an earlier statement, which suggested it did not recommend Leo Pharma’s atopic eczema treatment Adtralza (tralokinumab).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
England and Wales reject Leo Pharma's eczema drug
For subscribers
.jpg&w=384&q=75)
